
BioBiz Buzz Podcast: How Bioxodes is using tick saliva to create an ICH stroke treatment breakthrough
We use necessary cookies to make our website work. We also use optional statistical, functional and marketing cookies that you can choose to decline in your preference setting. For more information about the use of cookies or our use of data, see our Cookies notice or Privacy notice
Cookies settings I agree I disagreeCookies information
Our site uses tools, such as cookies, to analyze and improve your experience. You can unsubscribe below:
These settings will be kept for 24h
BioBiz Buzz Podcast: How Bioxodes is using tick saliva to create an ICH stroke treatment breakthrough
Accurate Diagnosis And Enrollment Criteria Improve Intracerebral Hemorrhage Research
How Bioxodes is rewriting the rules of haemorrhagic stroke treatment
Bioxodes plans to raise EUR 70m to bring to market its hemorrhagic stroke drug candidate – CEO
Celebrating Clinical Trials Day, Part 2: Trial Optimization In Action
Can Bioxodes end the dearth of haemorrhagic stroke drugs?
Reportage RTBF on Bioxodes (national TV)
With new data in stroke, Bioxodes looks to a series B
Bioxodes halts phase 2 stroke trial after successful interim review, plots registrational study
La société wallonne Bioxodes pourrait devenir la première à commercialiser un traitement contre l'AVC
Understanding neuroinflammation is key to new treatments for stroke
Six biomimicry biotech companies harnessing nature’s wisdom to develop breakthrough drug candidates